Skip to main content

Table 3 Characterisation of EVs in saliva and tears

From: Proteomic and histopathological characterisation of sicca subjects and primary Sjögren’s syndrome patients reveals promising tear, saliva and extracellular vesicle disease biomarkers

 

Mean particle size*

(nm)

Particles/mL*

CD9 + EVs**

S/N ratio MFI

Tear fluid

 Pool of patients with pSS (n = 9)

255 ± 40

5.0 E+08

1.04

 Pool of patients with non-SS (n = 14)

204 ± 8

1.2 E+09

1.22

 Pool of controls (n = 10)

215 ± 9

7.1 E+08

1.20

Saliva

 Patients with pSS (n = 9)

233 ± 17

1.9 E+10 ± 0.7E+9

4.32 ± 1.19

 Patients with non-SS (n = 14)

231 ± 13

1.0 E+10 ± 1.6E+9

3.98 ± 0.57

 Controls (n = 10)

264 ± 6

7.9 E+9 ± 1.6E+9

3.22 ± 0.98

  1. *Nanoparticle tracking analysis was conducted on EV joint fractions from pooled tear fluid (n = 9 pSS, n = 14 non-SS and n = 10 controls) and whole saliva (n = 9 pSS, n = 14 non-SS and n = 10 controls), to determine mean particle size of microvesicles and exosomes (nm ± SEM), in addition to concentrations of EVs (particles/ml ± SEM)
  2. **Detection of CD9+ EVs from joint fractions of pooled tear fluid (n = 9 pSS, n = 14 non-SS and n = 10 controls), and whole saliva (n = 9 pSS, n = 14 non-SS and n = 10 controls) was performed by immunoaffinity capture using anti-CD9 coated magnetic beads followed by flow cytometry analysis. The results were reported as signal to noise (S/N) ratios of median fluorescence intensity (MFI)
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us